DESONIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H32O6
Molecular Weight	416.5073
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO

InChI

InChIKey=WBGKWQHBNHJJPZ-LECWWXJVSA-N

InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848

Desonide is a topical glucocorticoid which was approved by FDA for the treatment of such conditions as eczema, psoriasis, atopic dermatitis, etc. The exact mechanism of drug action is unknown.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Atopic dermatitis 43 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician. Launch Date 1972
Eczema 46 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Seborrheic dermatitis 15 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Contact dermatitis 20 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Psoriasis 84 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972

Doses

Dose	Population	Adverse events
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3	unhealthy n = 425 Health Status: unhealthy Condition: Atopic dermatitis Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3	Disc. AE: Telangiectasia... AEs leading to discontinuation/dose reduction: Telangiectasia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	Disc. AE: Cushing's syndrome, Hypothalamic pituitary adrenal axis suppression... AEs leading to discontinuation/dose reduction: Cushing's syndrome Hypothalamic pituitary adrenal axis suppression Atrophy Striae Irritation skin Acneiform eruption Skin hypopigmentation Allergic contact dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Telangiectasia	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3	unhealthy n = 425 Health Status: unhealthy Condition: Atopic dermatitis Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3
Acneiform eruption	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Allergic contact dermatitis	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Atrophy	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Cushing's syndrome	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Hypothalamic pituitary adrenal axis suppression	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Irritation skin	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Skin hypopigmentation	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Striae	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21324lbl.pdf#page=4 Page: 4,8	yes		yes (co-administration study) Comment: Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide. If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21324lbl.pdf#page=4 Page: 4,8

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:204734	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:204734
ChemicalBook	CB2783466	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2783466
MolPort	MolPort-003-987-087	https://www.molport.com/shop/molecule-link/MolPort-003-987-087
Selleck Chemicals	Desonide	http://www.selleckchem.com/products/Desonide.html
ZINC	ZINC000004212851	http://zinc15.docking.org/substances/ZINC000004212851
eMolecules	31225502	https://www.emolecules.com/cgi-bin/more?vid=31225502
eMolecules	6842825	https://www.emolecules.com/cgi-bin/more?vid=6842825

PubMed

Title	Date	PubMed
Clinical comparison of alclometasone dipropionate and desonide ointments (0.05%) in the management of psoriasis.	1982	6754511
Allergic contact dermatitis from topical corticosteroids.	1989 Aug	2530056
Evaluation of cross-reactivity between budesonide and desonide.	2002 Aug	12423417
Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis.	2002 Aug	12121395
Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis.	2002 Jul	12072722
Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse.	2004	15550762
Overview on desonide 0.05%: a clinical safety profile.	2004 Jul-Aug	15303783
Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare.	2004 Sep	15324406
Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: a post-marketing surveillance study.	2004 Sep-Oct	17642640
[Connubial contact dermatitis to an inhaled corticosteroid].	2005 Feb	15798566
Comparison of the analysis of corticosteroids using different techniques.	2005 Jan	15700162
Seborrheic dermatitis.	2005 Jan-Feb	15654167
Erythematous scaling eyelids: patient history, exposure to allergens and irritants are keys to diagnosis.	2005 Jun	16001768
Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences.	2005 Mar-Apr	15767771
Rapid resolution of a common problem.	2005 May	15866247
Photochemistry of desonide, a non-fluorinated steroidal anti-inflammatory drug.	2006 Jun	16755054
Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis.	2007 Feb	17373176
Verdeso (desonide) Foam, 0.05%.	2007 Jan-Feb	17215617
A novel hydrogel vehicle formulated for the treatment of atopic dermatitis.	2007 Jul	17763596
Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis.	2007 Jun	17713152
Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis.	2007 May-Jun	17542883
Periorbital cutaneous neonatal lupus.	2007 May-Jun	17483660
Tega-dermabrasion.	2007 Sep	17721261
Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis.	2007 Sep 20	21289943
Desonide gel.	2007 Sep-Oct	17786103
Desonide foam 0.05%: safety in children as young as 3 months.	2008 Aug	18638631
Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome.	2008 Aug	18258739
What's your assessment? Severe seborrheic dermatitis.	2008 Dec	19241741
New and emerging trends in the treatment of atopic dermatitis.	2008 Feb 2	19920986
Adverse cutaneous drug reaction.	2008 Jan	19967009
Desonide foam: a review.	2008 Jan	18301804
Desonide: a review of formulations, efficacy and safety.	2008 Jul	18549345
Worrisome perioral rash on a young boy. Lip-licker's dermatitis.	2008 May	18556883
Direct injection LC/ESI-MS horse urine analysis for the quantification and identification of threshold substances for doping control. I. Determination of hydrocortisone.	2008 Sep	18407581
A simple and rapid ESI-LC-MS/MS method for simultaneous screening of doping agents in urine samples.	2009 Apr	20336223
Fixed drug eruption induced by atenolol.	2009 Apr 24	21437137
Rhabdomyomatous mesenchymal hamartoma: clinical overview and report of a case with spontaneous regression.	2009 Dec	20583694
Treatment of scalp and facial seborrheic dermatitis with desonide hydrogel 0.05%.	2009 Feb	20967179
[Streptococcal perianal dermatitis and guttate psoriasis].	2009 Jan	19171228
Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report.	2009 Jul 2	19829884
Manifestations of cutaneous sarcoidosis: a case report of an African American woman.	2009 Jun	19585935
An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face.	2009 Nov-Dec	19878781
Drugs associated with more suicidal ideations are also associated with more suicide attempts.	2009 Oct 2	19798416
Vitiligo after diphencyprone for alopecia areata.	2010	20585597
Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.	2010	19907136
Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance.	2010 Apr	20514788
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories.	2010 Apr	20155493
Update on the management of chronic eczema: new approaches and emerging treatment options.	2010 Jul 28	21437065
Pediatric atopic dermatitis: a review of the medical management.	2010 Sep	20628042

Patents

Sample Use Guides

In Vivo Use Guide

Desonide Cream, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition.

Route of Administration: Topical

In Vitro Use Guide

Unknown

Name

Type

Language

DESONIDE

Official Name

English

DESONIDE [MART.]

Common Name

English

DESONIDE COMPONENT OF TRIDESILON

Common Name

English

DESONIDE [ORANGE BOOK]

Common Name

English

TRIDESILON COMPONENT DESONIDE

Common Name

English

DESONIDE [USP IMPURITY]

Common Name

English

DESONIDE [USAN]

Common Name

English

DESONIDE [USP MONOGRAPH]

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (11.BETA.,16.ALPHA.)-

Common Name

English

VERDESO

Brand Name

English

11β,16α,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone

Common Name

English

BUDESONIDE IMPURITY F [EP IMPURITY]

Common Name

English

DESOWEN

Brand Name

English

DESONIDE [USP-RS]

Common Name

English

D-2083

Code

English

DESONIDE [VANDF]

Common Name

English

D2083

Code

English

desonide [INN]

Common Name

English

NSC-759226

Code

English

Desonide [WHO-DD]

Common Name

English

DESONIDE [MI]

Common Name

English

DESONATE

Brand Name

English

Classification Tree Code System Code

WHO-ATC

S01BA11